Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Epidemiological biliary tract cancer characterization: A patient cohort from the Spanish RETUD registry.
Authors
Teresa Macarulla
Hospital Universitario Vall d'Hebron, Barcelona, Spain
Teresa Macarulla , Maialen Barrero , Jorge Adeva , Oscar Alfredo Castillo Trujillo , Andrés J. Muñoz Martín , Paloma Peinado Martin , Helena Verdaguer , Eva Martinez de Castro , Miriam Lobo De Mena , Mónica Granja , Rosa Rodríguez Alonso , Noelia Garcia Cid , Elena Asensio-Martínez , Ruth Vera , Begoña Graña , Ismael Ghanem , Inmaculada Alés , Raquel Molina , Berta Laquente , Enrique Aranda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Other
DOI
10.1200/JCO.2022.40.4_suppl.480
Abstract #
480
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Clinical outcomes analysis of TP53-mutated advanced and metastatic biliary tract cancers.
First Author: Sunyoung S. Lee
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Characterizing outcomes of ERBB2-amplified biliary tract cancer.
First Author: Daniel Aaron Fox
Poster
2020 Gastrointestinal Cancers Symposium
SHR-1210 combined with GEMOX as first-line treatment in patients with advanced biliary tract cancer.
First Author: Xiaofeng Chen
Poster
2015 Gastrointestinal Cancers Symposium
A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study.
First Author: Francesco Leone